Shelf Life: Generally 24 months, depending on storage conditions
II. Drug Characteristics
Mechanism of Action: Afatinib is an irreversible inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases developed by Boehringer Ingelheim. It irreversibly inhibits the activity of this tyrosine kinase by undergoing a Michael addition reaction with the thiol group of cysteine at position 797 in EGFR.
Indications: It is primarily used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), particularly metastatic NSCLC with EGFR exon 19 deletions or exon 21 mutations (L858R). Additionally, it has a certain efficacy in patients with HER2-positive advanced cancer.
Dosage and Administration: The dose and administration are typically determined based on the patient's specific condition and the doctor's recommendation. The recommended dose is usually once daily, taken orally.
III. Physical and Chemical Properties
Density: Approximately 1.380 (specific values may vary depending on the preparation method and purity)
Solubility: It has a certain solubility in appropriate solvents, facilitating preparation and use.
Stability: It is relatively stable under normal temperature and pressure but should be avoided from prolonged exposure to high temperatures, humidity, or light.
